USA flag logo/image

An Official Website of the United States Government

OF DIAGNOSING AND MONITORING ATHEROSCLEROSIS.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
477
Program Year/Program:
1983 / SBIR
Agency Tracking Number:
477
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Genetic Systems Corp
3005 First Ave. Seattle, WA 98121
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1983
Title: OF DIAGNOSING AND MONITORING ATHEROSCLEROSIS.
Agency: HHS
Contract: N/A
Award Amount: $73,471.00
 

Abstract:

OF DIAGNOSING AND MONITORING ATHEROSCLEROSIS. THIS WILL BE BASED ON A METHOD INCORPORATING BLOOD CLEARANCE OF RADIOLABELD ANTIBODIES DIRECTED AGAINST SPECIFIC CONSTITUENTS OF ATHEROSCLEROTIC PLAQUE. FOR THIS PURPOSE, THEY WILL PREPARE A PANEL OF MONOCLONAL ANTIBODIES AGAINST DIFFERENT COMPONENTS OF THE ATHEROSCLEROTIC PLAQUE. ANTIBODIES AGAINST PLAQUE-SPECIFIC OR PLAQUE-ASSOCIATED MARKERS WILL BE SELECTED BY COMPARATIVE IMMUNOCYTOCHEMICAL ANALYSIS ON FROZEN SECTIONS OF ATHEROSCLEROTIC AND NORMAL ARTERIES FROM NON-HUMAN PRIMATES AND HUMANS. THIS WILL ENABLE THE IDENTIFICATION AND SELECTION OF ANTIBODIES AGAINST ANTIGENS THAT ARE EXPOSED IN THE LUMEN OF THE BLOOD VESSEL. MONOCLONAL ANTIBODIES AGAINST INDIVIDUAL PLAQUE ANTIGENS WILL BE RADIOLABELED WITH (125)I AND INJECTED INTO NON-HUMAN PRIMATES FOR BLOOD CLEARANCE STUDIES. TO CONTROL FOR DIFFERENCES THAT MAY EXIST IN THE VASCULAR SYSTEM OF DIFFERENT ANIMALS, THEY WILL UTILIZE A SECOND (131)I RADIOLABELED MONOCLONAL ANTIBODY WHICH IS KNOWN NOT TO BIND TO ANTIGENS IN THE VASCULAR SYSTEM. BY COMPARING OVER TIME THE RATIO OF THESE TWO ANTIBODIES IN BLOOD, IT MAY BE POSSIBLE TO DETECT SPECIFIC CLEARANCE OF THE MONOCLONAL ANTIBODY THAT DETECTS ANTIGENS WITHIN THE ATHEROSCLEROTIC PLAQUE. THE EXTENT RATE OF ANTIBODY CLEARANCE SHOULD BE REPRESENTATIVE OF THE AMOUNT OF ATHEROSCLEROTIC PLAQUE IN THE CIRCULATORY SYSTEM. IF SUCCESSFUL, THIS METHOD COULD BE USED FOR EARLY IN VIVO DIAGNOSIS OF ATHEROSCLEROSIS AND FOR MONITORING THE RESULTS OF THERAPY IN INDIVIDUALS.

Principal Investigator:

Lynn c. goldstein
PRINCIPAL INVESTIGATOR
2066244300

Business Contact:

Small Business Information at Submission:

Genetic Systems Corpon
3005 First Avenue Seattle, WA 98121

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No